The aim of this study was to investigate whether ambient nitrogen dioxide (NO2) and carbon monoxide (CO) increase the risk for age-related macular degeneration (AMD). This is a longitudinal population-based study using the data on Taiwan National Health Insurance Program between year 2000 and 2010. From the nationwide dataset, we enrolled subjects aged 50 or older and the annually total NO2 and CO exposure was calculated from 1998 to 2010 for each subject. The Cox proportional hazard regression was used to estimate the HRs with adjustment for other variables. A total of 39,819 AMD-free residents were enrolled, and 1442 participants developed AMD during the 11 -year follow-up. Compared with the lowest exposure quartile, the highest quartile of each air pollutant was associated with an increased risk for AMD. The adjusted HR was 1.91 (95% CI 1.64 to 2.23, p<0.001) for the highest NO2 quartile, and was 1.84 (95% CI 1.5 to 2.15, p<0.001) for the highest CO quartile. In this study, chronic exposure to the highest quartile of ambient NO2 or CO significantly increases the risk for AMD.
- traffic-related pollutants
- nitrogen dioxide (NO2)
- carbon monoxide (CO)
- age-related macular degeneration (AMD)
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors Conceptualization: K-HC, P-YH, S-HHJ, and C-LL; methodology: K-HC, C-JL, S-HHJ, and C-LL; formal analysis: K-HC and C-LL; investigation: all authors; writing (original draft preparation): K-HC; writing (review and editing): S-HHJ and C-LL; visualization: all authors; supervision: S-HHJ and C-LL; project administration: S-HHJ and C-LL.
Funding This study was supported by the grants from the Asia University-CMU Hospital intramural grant (ASIA-106-CMUH-18), Tungs' Taichung Metroharbor Hospital (TTMHH-108R0029), Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW108-TDU-B-212-133004), Taiwan Ministry of Science and Technology (MOST 107-2321-B-039-004 and MOST 106-3114-8-039-002), the “Drug Development Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan.
Competing interests None declared.
Ethics approval The study was approved by the Ethics Review Board of China Medical University and Hospital, Taiwan (CMUH-104-REC2-115).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data are available from the NHIRD published by Taiwan National Health Insurance Bureau. Due to the ‘Personal Information Protection Act’, data cannot be made publicly available (http://nhird.nhri.org.tw/en/index.html).
Patient consent for publication Not required.